Investor Relations

Rigel's Mission

Rigel Pharmaceuticals is a biotechnology company dedicated to developing and commercializing novel, small molecule drugs that significantly improve the lives of patients with immune and hematological disorders, cancer and rare diseases.

Rigel to Present at the J.P. Morgan Healthcare Conference

View Press Release View All

Jan 10, 2022 • 8:40am EST

Rigel Pharmaceuticals Provides Business Update

Dec 21, 2021 • 8:30am EST

Fostamatinib Meets Primary Endpoint in Phase 3 Trial in Japan for Treatment of Chronic Immune Thrombocytopenia

Dec 16, 2021 • 9:00am EST

Rigel Appoints Kamil Ali-Jackson to Board of Directors

January 2022

View Presentation

40th Annual J.P. Morgan Healthcare Conference

View Event View All

Q3 2021

Quarter Ended Sep 30, 2021

Earnings Release

PDF HTML

Audio

Earnings Webcast

Earnings Presentation

PDF

10-Q

PDF HTML

XBRL

ZIP XLS HTML

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2020

Investor Contact Information

Company

Rigel Pharmaceuticals, Inc.
1180 Veterans Blvd
South San Francisco, CA 94080